The circulating and central endocannabinoid system in obesity and weight loss

被引:4
|
作者
Mattelaer, Nele [1 ,2 ,3 ]
van der Schueren, Bart [1 ,4 ]
Van Oudenhove, Lukas [2 ,3 ]
Weltens, Nathalie [2 ,3 ]
Vangoitsenhoven, Roman [1 ,4 ]
机构
[1] Katholieke Univ Leuven, Dept Chron Dis & Metab, Clin & Expt Endocrinol, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Chron Dis & Metab, Lab Brain Gut Axis Studies, Translat Res Gastrointestinal Disorders, Leuven, Belgium
[3] Katholieke Univ Leuven, Leuven Brain Inst, Leuven, Belgium
[4] Univ Hosp Leuven, Dept Endocrinol, Leuven, Belgium
关键词
CANNABINOID-1 RECEPTOR BLOCKER; CARDIOMETABOLIC RISK-FACTORS; Y GASTRIC BYPASS; CB1; RECEPTOR; PLASMA; RIMONABANT; HUMANS; ANANDAMIDE; INSULIN; 2-ARACHIDONOYLGLYCEROL;
D O I
10.1038/s41366-024-01553-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Major advances have been made in obesity treatment, focusing on restoring disturbances along the gut-brain axis. The endocannabinoid system (ECS) is a neuromodulatory signaling system, present along the entire gut-brain axis, that plays a critical role in central and peripheral regulation of food intake and body weight. Evidence on the impact of weight loss on the ECS is, however, more limited. Therefore, we set out to review the existing literature for changes in central and circulating endocannabinoid levels after bariatric surgery and other weight loss strategies in humans. The PubMed, Embase and Web of Science databases were searched for relevant articles. Fifty-six human studies were identified. Most studies measuring circulating 2-arachidonoylglycerol (2-AG) found no difference between normal weight and obesity, or no correlation with BMI. In contrast, studies measuring circulating arachidonoylethanolamine (AEA) found an increase or positive correlation with BMI. Two studies found a negative correlation between BMI and cannabinoid receptor type 1 (CB1) receptor availability in the brain. Only one study investigated the effect of pharmacological weight management on circulating endocannabinoid concentrations and found no effect on AEA concentrations. So far, six studies investigated potential changes in circulating endocannabinoids after bariatric surgery and reported conflicting results. Available evidence does not univocally support that circulating endocannabinoids are upregulated in individuals with obesity, which may be explained by variability across studies in several potential confounding factors (e.g. age and sex) as well as heterogeneity within the obesity population (e.g. BMI only vs. intra-abdominal adiposity). While several studies investigated the effect of lifestyle interventions on the circulating ECS, more studies are warranted that focus on pharmacologically and surgically induced weight loss. In addition, we identified several research needs which should be fulfilled to better understand the role of the ECS in obesity and its treatments.
引用
收藏
页码:1363 / 1382
页数:20
相关论文
共 50 条
  • [1] Obesity and the Endocannabinoid System: Circulating Endocannabinoids and Obesity
    Matias I.
    Gatta-Cherifi B.
    Cota D.
    Current Obesity Reports, 2012, 1 (4) : 229 - 235
  • [2] Investigations of the Endocannabinoid System in Adipose Tissue Effects of Obesity/Weight Loss and Treatment Options
    Bennetzen, Marianne Faurholt
    DANISH MEDICAL BULLETIN, 2011, 58 (04)
  • [3] Dynamics of circulating microparticles in obesity after weight loss
    Elena Campello
    Eva Zabeo
    Claudia M. Radu
    Luca Spiezia
    Mirto Foletto
    Luca Prevedello
    Sabrina Gavasso
    Cristiana Bulato
    Roberto Vettor
    Paolo Simioni
    Internal and Emergency Medicine, 2016, 11 : 695 - 702
  • [4] Dynamics of circulating microparticles in obesity after weight loss
    Campello, Elena
    Zabeo, Eva
    Radu, Claudia M.
    Spiezia, Luca
    Foletto, Mirto
    Prevedello, Luca
    Gavasso, Sabrina
    Bulato, Cristiana
    Vettor, Roberto
    Simioni, Paolo
    INTERNAL AND EMERGENCY MEDICINE, 2016, 11 (05) : 695 - 702
  • [5] Weight loss increases circulating levels of ghrelin in human obesity
    Hansen, TK
    Dall, R
    Hosoda, H
    Kojima, M
    Kangawa, K
    Christiansen, JS
    Jorgensen, JOL
    CLINICAL ENDOCRINOLOGY, 2002, 56 (02) : 203 - 206
  • [6] The endocannabinoid system and the treatment of obesity
    Pagotto, U
    Vicennati, V
    Pasquali, R
    ANNALS OF MEDICINE, 2005, 37 (04) : 270 - 275
  • [7] A role for the endocannabinoid system in obesity
    Valenzuela, Carina
    Aguirre, Carolina
    Castillo, Valeska
    Maria Ronco, Ana
    Llanos, Miguel
    REVISTA MEDICA DE CHILE, 2010, 138 (05) : 621 - 629
  • [8] Dysregulation of the endocannabinoid system in obesity
    Engeli, S.
    JOURNAL OF NEUROENDOCRINOLOGY, 2008, 20 : 110 - 115
  • [9] The peripheral endocannabinoid system in human obesity
    Engeli, S
    Feldpausch, M
    Gorzelniak, K
    Janke, J
    Batkai, S
    Pacher, P
    Luft, F
    Sharma, A
    Jordan, J
    OBESITY RESEARCH, 2005, 13 : A13 - A13
  • [10] The endocannabinoid system, Obesity, and insulin resistance
    Engeli S.
    Current Cardiovascular Risk Reports, 2008, 2 (1) : 72 - 78